<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271713</url>
  </required_header>
  <id_info>
    <org_study_id>ML 19472</org_study_id>
    <nct_id>NCT00271713</nct_id>
  </id_info>
  <brief_title>Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)</brief_title>
  <official_title>Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Postmenopausal Osteoporosis Without Vertebral Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy:

      To investigate changes of structural bone properties in vivo using 3DpQCT (&quot;Xtreme&quot; CT,
      Scanco) in monthly oral ibandronate therapy for women with postmenopausal osteoporosis.

      Major structural bone parameters which determine bone strength and predict fracture risk
      earlier and more precisely are measurable in vivo by 3DpQCT.

      Safety:

      To assess the tolerability and safety of ibandronate therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BV/TV and trab. Sp. measured by 3D pQCT device</measure>
    <time_frame>Baseline and after 3, 6, 9 and 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>ibandronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo monthly plus 500mg calcium and 800 UI vitamin D daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate, calcium and vitamin D</intervention_name>
    <description>1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or</description>
    <arm_group_label>ibandronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo,calcium and vitamin D</intervention_name>
    <description>2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 60 and 75 years

          -  Menopause &gt; 5 years

          -  Spine (L1 - L4) or hip BMD ≤ -2.0 and &gt; -3.5 SD T-score measured by DXA

          -  Patients who, in the opinion of the investigator, are able and willing to comply with
             the protocol for its duration

          -  Written informed consent

          -  3DpQCT measurable at both skeletal sites, distal tibia and radius

        Exclusion Criteria:

          -  Spine or hip BMD ≤ -3,5 SD T-Score measured by DXA

          -  Vertebral fractures

          -  Multiple (&gt;2) low trauma peripheral fractures

          -  Disease/disorder known to influence bone metabolism

          -  History of major upper gastro-intestinal (GI) disease

          -  Diagnosed malignant disease within the previous 10 years

          -  Previous treatment with a bisphoshonate at any time

          -  Treatment with fluoride for osteoporosis (dose greater than 10 mg/day) within the last
             12 months, or for more than 2 years (total duration)

          -  Treatment with PTH and similar agents or strontium ranelate at any time

          -  Treatment with other drugs affecting bone metabolism within the last 6 months

          -  Chronic systemic corticosteroid treatment

          -  Estrogens, progestins, SERMs, anabolic steroids, active vitamin D
             analogues/metabolites, calcitonin

          -  Calcineurin inhibitors (e.g. cyclosporine, tacrolimus) or methotrexate

          -  Total serum calcium &lt; 2.2 mmol/l or &gt; 2.6 mmol/l

          -  Vitamin D deficiency (serum 25-hydroxy vitamin D &lt; 12 ng/ ml)

          -  ALT above triple upper limit of normal range

          -  Renal impairment (serum creatinine &gt; 210 µmol/l)

          -  Contra-indications for ibandronate, calcium or vitamin D

          -  Employees of the Centre for Muscle and Bone Research, or their relatives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Felsenberg, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin, Berlin, 12200, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.charite.de/zmk/</url>
    <description>Homepage of the Centre for Muscle and Bone Research</description>
  </link>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2006</study_first_submitted>
  <study_first_submitted_qc>January 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2006</study_first_posted>
  <last_update_submitted>January 27, 2009</last_update_submitted>
  <last_update_submitted_qc>January 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Charite University, Berlin, Germany</name_title>
    <organization>center for muscle and bone research</organization>
  </responsible_party>
  <keyword>bone structure</keyword>
  <keyword>ibandronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

